auc Search Results


analytical ultracentrifugation auc  (Danaher Inc)
96
Danaher Inc analytical ultracentrifugation auc
Analytical Ultracentrifugation Auc, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc06344894-57-0-11?v=Danaher+Inc
Average 96 stars, based on 1 article reviews
analytical ultracentrifugation auc - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
gc fame analysis  (Avanti Polar)
90
Avanti Polar gc fame analysis
Gc Fame Analysis, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc08452012-255-17-9?v=Avanti+Polar
Average 90 stars, based on 1 article reviews
gc fame analysis - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc  (AbbVie Inc)
90
AbbVie Inc auc
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc11842418-205-20-34?v=AbbVie+Inc
Average 90 stars, based on 1 article reviews
auc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
area under the curve (auc) calculation  (GraphPad Software Inc)
90
GraphPad Software Inc area under the curve (auc) calculation
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Area Under The Curve (Auc) Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pm35176632-115-6-14?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
area under the curve (auc) calculation - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc function of prism  (GraphPad Software Inc)
90
GraphPad Software Inc auc function of prism
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc Function Of Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc05558854-607-13-14?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
auc function of prism - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc  (KBI Biopharma)
90
KBI Biopharma auc
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc, supplied by KBI Biopharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc08099603__mmc2-92-44-61?v=KBI+Biopharma
Average 90 stars, based on 1 article reviews
auc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc calculation  (GraphPad Software Inc)
90
GraphPad Software Inc auc calculation
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc06658676-102-3-11?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
auc calculation - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc analysis  (GraphPad Software Inc)
90
GraphPad Software Inc auc analysis
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc05731250-592-4-10?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
auc analysis - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
aucs generated with graphpad prism  (GraphPad Software Inc)
90
GraphPad Software Inc aucs generated with graphpad prism
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Aucs Generated With Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc06347826-107-1-5?v=GraphPad+Software+Inc
Average 90 stars, based on 1 article reviews
aucs generated with graphpad prism - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc comparison  (MedCalc Software Ltd)
90
MedCalc Software Ltd auc comparison
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc Comparison, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pm29867134-59-12-17?v=MedCalc+Software+Ltd
Average 90 stars, based on 1 article reviews
auc comparison - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc  (Akademie der Unfallchirurgie GmbH)
90
Akademie der Unfallchirurgie GmbH auc
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc, supplied by Akademie der Unfallchirurgie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/pmc11354497-74-7-8?v=Akademie+der+Unfallchirurgie+GmbH
Average 90 stars, based on 1 article reviews
auc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
auc–sas  (SAS institute)
90
SAS institute auc–sas
Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, <t>AUC</t> area under curve, F max maximum <t>fluorescence,</t> <t>TTT</t> time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)
Auc–Sas, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/auc/10__1107_slash_s1600576723002406-31-17-8?v=SAS+institute
Average 90 stars, based on 1 article reviews
auc–sas - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, AUC area under curve, F max maximum fluorescence, TTT time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)

Journal: Acta Neuropathologica

Article Title: A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease

doi: 10.1007/s00401-025-02853-y

Figure Lengend Snippet: Comparison of CSF SAA results between PD/DLB and other neurodegenerative entities. PD Parkinson’s disease, DLB dementia with Lewy bodies, CON control, MSA multiple system atrophy, PSP progressive supranuclear palsy, AD Alzheimer’s disease, FTD frontotemporal dementia, RFU relative fluorescence units, AUC area under curve, F max maximum fluorescence, TTT time to threshold, av.: average. a The curve characteristics of individual SAA reactions split for diagnoses are presented for PD/DLB (red, n = 46), MSA (blue, n = 31), PSP (yellow, n = 32), and CON (green, n = 20), highlighting the Lewy-fold specificity of the SAA for PD/DLB cases compared to no SAA reactions in MSA and CON cases that stay negative for 144 h. RFU values are normalized to the maximum intensity of fluorescence of the respective experimental plate. Each curve represents the average of the group ± standard error of the mean. b Comparison of the AUC of each group; each point depicts the median AUC for the replicates of the respective individual. c Comparison of the F max of each group; each point depicts the median F max for the replicates of the respective individual. Statistical analyses were conducted using Wilcoxon tests, resulting in a significance of p < 0.0001 (****) between PD/DLB against the other groups, except for FTD (** p ≤ 0.01)

Article Snippet: Of note, 2 publications compared different SAAs in the same study: Russo et al. [ ] analyzed F max , AUC, TTT, T 50 and endpoint dilution (SD 50 ) across three different laboratories (AbbVie, Amprion and Caughey).

Techniques: Comparison, Control, Fluorescence

Correlation of different SAA parameters with core clinical features

Journal: Acta Neuropathologica

Article Title: A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease

doi: 10.1007/s00401-025-02853-y

Figure Lengend Snippet: Correlation of different SAA parameters with core clinical features

Article Snippet: Of note, 2 publications compared different SAAs in the same study: Russo et al. [ ] analyzed F max , AUC, TTT, T 50 and endpoint dilution (SD 50 ) across three different laboratories (AbbVie, Amprion and Caughey).

Techniques: